-
Jul 18, 2024 | 
onclive.com | Tycel J. Phillips
CommentaryVideoJuly 18, 2024Author(s):Tycel Phillips, MD, discusses the evolution of treatment for patients with myelodysplastic syndromes, highlighting the future of this treatment paradigm.
-
Jul 11, 2024 | 
onclive.com | Tycel J. Phillips
CommentaryVideoJuly 11, 2024Author(s):Tycel Phillips, MD, discusses the evolution of treatment strategies for patients with either chronic lymphocytic leukemia or mantle cell lymphoma.
-
Jul 9, 2024 | 
cancernetwork.com | Tycel J. Phillips
CancerNetwork® spoke with Tycel Phillips, MD, an associate professor in the Division of Hematology and Hematopoietic Stem Cell Transplantation at the City of Hope National Cancer Center in Duarte, California, about what the FDA accelerated approval of epcoritamab-bysp (Epkinly) might mean for patients with relapsed/refractory follicular lymphoma.1 The approval for epcoritamab in this population was supported by efficacy findings from the phase 1/2 EPCORE NHL-1 trial (NCT03625037).2 Phillips...
-
Jul 8, 2024 | 
cancernetwork.com | Brad S. Kahl |Tycel J. Phillips
2 Commerce Drive Cranbury, NJ 08512
-
Jul 8, 2024 | 
cancernetwork.com | Tycel J. Phillips
Tycel Phillips, MD, spoke with CancerNetwork® ahead of the FDA’s accelerated approval of epcoritamab-bysp (Epkinly) for patients with relapsed/refractory follicular lymphoma to discuss how this agent may impact the treatment paradigm.
-
Jul 2, 2024 | 
cancernetwork.com | Tycel J. Phillips
All patient subgroups with relapsed/refractory mantle cell lymphoma (MCL) appeared to benefit from treatment with glofitamab-gxbm (Columvi), even among groups with or without prior exposure to Bruton’s tyrosine kinase (BTK) inhibitors and those with COVID-19 related events, according to Tycel Phillips, MD.
-
Jun 28, 2024 | 
onclive.com | Tycel J. Phillips
Tycel Phillips, MD, hematologist-oncologist, associate professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, discusses the evolution of treatment for patients with mantle cell lymphoma (MCL). Following his presentation at an OncLive® State of Science Summit™ on hematology, Phillips says oncologists are gradually transitioning away from using chemoimmunotherapy in patients with MCL.
-
Jun 27, 2024 | 
cancernetwork.com | Brad S. Kahl |Tycel J. Phillips
June 27, 2024By The panelists evaluate the preliminary efficacy findings from the ECHO trial and address how the COVID-19 pandemic influenced overall survival outcomes in the study. What are your initial impressions of the efficacy data from ECHO? How did COVID impact OS for this trial data? Do you have clinical experience with BTKi’s in the frontline setting? If so, please share your experience. Related Content Related Content
-
May 4, 2024 | 
onlinelibrary.wiley.com | Sam Yuen |Tycel J. Phillips |Rajat Bannerji |Paula Marlton
1 INTRODUCTION Advanced-stage follicular lymphoma (FL) has recurrent relapses and is incurable with standard treatments.1 Diffuse large B-cell lymphoma (DLBCL), although potentially curable with initial anthracycline-based chemoimmunotherapy, presents as relapsed/refractory (R/R) disease in 40% of patients.1 Therefore, novel treatment options with improved efficacy and safety are needed for these B-cell non-Hodgkin lymphoma (NHL) subtypes.
-
Apr 28, 2024 | 
mdpi.com | Jonathan Weiss |Tycel J. Phillips
All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.
